Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | NTRK1 amp |
Therapy | Larotrectinib |
Indication/Tumor Type | esophagus squamous cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NTRK1 amp | esophagus squamous cell carcinoma | predicted - sensitive | Larotrectinib | Case Reports/Case Series | Actionable | In a clinical case study, Vitrakvi (larotrectinib) resulted in a partial response with regression of both the primary tumor and metastatic lesions within 6 weeks from the start of treatment in a patient with squamous cell esophageal carcinoma with NTRK1 amplification (PMID: 32323889). | 32323889 |
PubMed Id | Reference Title | Details |
---|---|---|
(32323889) | Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification. | Full reference... |